Medtronic's SYMPLICITY HTN-3 Long-Term Data Presented
September 18, 2022—Medtronic announced the presentation of long-term results from the SYMPLICITY HTN-3 clinical trial. In the randomized control
Source: evtoday.com
Interventional Cardiovascular Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Interventional Cardiovascular Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Interventional Cardiovascular Programs Today - Breaking & Trending Today
Study: Medtronic renal denervation reduces blood pressure
Medtronic announced study data demonstrating significant blood pressure reduction with the Symplicity renal denervation system.
Source: massdevice.com
TCT 2022: SYMPLICITY HTN-3 trial data show sustained long-term blood pressure reductions with Medtronic renal denervation procedure
Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The LancetData a...
Source: businessinsider.com
Investegate |Amarin Corporation plc Announcements | Amarin Corporation plc: New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
Investegate announcements from Amarin Corporation plc, New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
Source: investegate.co.uk
New REDUCE-IT Data Show VASCEPA/VAZKEPA (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
26.08.2022 - - Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses - - Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 ... Seite 1
Source: wallstreet-online.de